SCHEMBL10245095

SCHEMBL10245095

O=C(c1cc(NSc2ccc(OC(F)(F)F)cc2)ccc1F)c1c[nH]c2ncc(Cl)cc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 8/20 0.42
ABL1 P00519 8/20 0.41
BMPR1B O00238 1/20 0.41
PLK4 O00444 1/20 0.41
PIR O00625 1/20 0.41
AURKA O14965 1/20 0.41
DCLK1 O15075 1/20 0.41
EPHB6 O15197 1/20 0.41
RIPK2 O43353 1/20 0.41
STK16 O75716 1/20 0.41
OXSR1 O95747 1/20 0.41
MAP4K4 O95819 1/20 0.41
RAF1 P04049 1/20 0.41
LCK P06239 1/20 0.41
FYN P06241 1/20 0.41
FES P07332 1/20 0.41
CSF1R P07333 1/20 0.41
YES1 P07947 1/20 0.41
LYN P07948 1/20 0.41
HCK P08631 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10246521 0.91 BRAF (0.41) BRAFABL1BMPR1BPLK4PIR
SCHEMBL298193 0.83 CYP2C9 (0.47) BRAFABL1BMPR1BPLK4PIR
SCHEMBL298324 0.78 CYP3A4 (0.47) BRAFABL1BMPR1BPLK4PIR
SCHEMBL299000 0.72 BRAF (0.51) BRAFABL1BMPR1BPLK4PIR
SCHEMBL4570629 0.72 BRAF (0.53) BRAFABL1BMPR1BPLK4PIR
SCHEMBL299148 0.71 BRAF (0.49) BRAFABL1BMPR1BPLK4PIR
SCHEMBL27795046 0.71 BRAF (0.54) BRAFABL1BMPR1BPLK4PIR
SCHEMBL297193 0.71 BRAF (0.53) BRAFABL1BMPR1BPLK4PIR
SCHEMBL12703497 0.71 BRAF (0.59) BRAFABL1BMPR1BPLK4PIR
SCHEMBL298889 0.71 CCR9 (0.50) BRAFABL1BMPR1BPLK4PIR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS BRAF, RAF1, ARAF BRAF 1/4885ABL1 698/4885BMPR1B 4719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.